Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342510 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19114776 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18736226 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18573712 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19429486 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19428703 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189203 | 0.98 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL26816830 | 0.90 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13448994 | 0.90 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL27369066 | 0.89 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.